N4 Pharma PLC Total Voting Rights (4646R)
October 31 2023 - 3:00AM
UK Regulatory
TIDMN4P
RNS Number : 4646R
N4 Pharma PLC
31 October 2023
31 October 2023
N4 Pharma plc
("N4 Pharma" or the "Company")
Total Voting Rights
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that the total number of shares in issue
and total voting rights as at the date of this announcement is
268,780,349 ordinary shares of 0.4 pence each ("Ordinary
Shares").
The total issued share capital of the Company consists of
268,780,349 Ordinary Shares. The Company does not hold any Ordinary
Shares in Treasury. Therefore, the total current voting rights in
the Company is 268,780,349 and this figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the FCA's Disclosure Guidance and Transparency
Rules.
Enquiries:
N4 Pharma plc
Nigel Theobald, CEO Via IFC Advisory
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska (Corporate
Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees
(Corporate Broking)
Turner Pope Investments (TPI) Limited Tel: +44(0)20 3657
0050
Joint Broker
Andy Thacker
James Pope
IFC Advisory Ltd Tel: +44(0)20 3934
6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for oncology, gene therapy and vaccines using
its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens in these fields to use Nuvec(R) as the
delivery vehicle for these antigens. As these products progress
through pre-clinical and clinical programs, N4 Pharma will seek to
receive upfront payments, milestone payments and ultimately royalty
payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRNKABPABDDOKB
(END) Dow Jones Newswires
October 31, 2023 03:00 ET (07:00 GMT)
N4 Pharma (AQSE:N4P.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
N4 Pharma (AQSE:N4P.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024